Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship five of which are from the Nuffield Department of Medicine. All were selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

The Academy of Medical Sciences
  • For his pioneering work in the pathophysiology and treatment of severe malaria, antimalarial drug resistance and improvement of intensive care practice in resource-limited settings, Professor Arjen Dondorp of the Centre for Tropical Medicine and Global Health (Nuffield Department of Medicine) becomes a Fellow. He led large multinational trials in Asia and Africa that demonstrated parenteral artesunate is superior to quinine in preventing death from severe malaria in both adults and children. He also organised the pivotal trials showing that artemisinin resistance in falciparum malaria had emerged on the Cambodian-Thai border, starting an extensive research programme on multidrug resistant malaria, an important threat to malaria control.
  • Professor Sarah Gilbert of the Jenner Institute (Nuffield Department of Medicine) becomes a Fellow for her leading role in the development and design of the Oxford/AstraZeneca Covid-19 vaccine, alongside pioneering work to develop vaccines for other life-threatening diseases with pandemic potential including influenza, Nipah, Lassa and MERS. She oversaw the development of the ChAdOx1 viral vector that provided the platform technology for such a rapid vaccine development effort.
  • For his tireless clinical and epidemiological research on a wide range of emerging and epidemic infections spanning over 15 years, Professor Peter Horby of the Centre for Tropical Medicine and Global Health (Nuffield Department of Medicine) is named a Fellow at the Academy. He is co-lead of the RECOVERY trial – the world's largest trial of COVID-19 treatments – as well as director of Epidemic Diseases Research Group Oxford (ERGO) and International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), which are both engaged in several international programmes of clinical and epidemiological research to prepare for and respond to emerging infections that may develop into epidemics or pandemics.
  • Professor Marian Knight of the National Perinatal Epidemiology Unit (Nuffield Department of Population Health) becomes a Fellow for her research that addresses clinical questions concerning rare and severe complications of pregnancy and early life through national observational studies. Her work has enabled the team leading the aforementioned RECOVERY trial to collect information on pregnant women taking part through the UK Obstetric Surveillance System (UKOSS).
  • Professor Rose McGready of the Centre for Tropical Medicine and Global Health (Nuffield Department of Medicine) is named a Fellow for her leadership of the maternal malaria research sphere. During her tenure at the Shoklo Malaria Research Unit on the Thailand-Myanmar border, she has provided detailed knowledge of the burden and effects of malaria infections on pregnant women and new-borns, leading the world in the safe use of artemisinin derivatives in pregnancy. Focussing on maternal and child health, her research work has been translated into clinical practice and resulted in dramatic improvements in the health of marginalized women in South East Asia and beyond.

Similar stories

Oxford’s RECOVERY trial team amongst MRC‘s Outstanding Team Impact prize finalists

The inaugural MRC Impact Prize recognises teams who have made outstanding impacts in health and medical research. The winners will be announced at a ceremony in the spring.

Constant genetic surveillance needed to counter multidrug-resistant malaria strains

Continual monitoring of genetic changes in parasite populations is a powerful tool for analysing malaria outbreaks and identifying emerging multidrug-resistant malaria strains, say researchers from NDM’s Mahidol-Oxford Tropical Medicine Research Unit (MORU).

Lancet study informs WHO guidelines for the treatment of malaria in pregnancy

The study from the Worldwide Antimalarial Resistance Network (WWARN) provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Leedham Lab receives funding to improve bowel cancer treatments

The Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over £2m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study provides important insights into TB correlates of protection

Researchers from the Nuffield Department of Medicine’s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.